

**bsm-41634M**

**[ Primary Antibody ]**

## **SARS-CoV-2 (2019-nCoV) Spike Neutralizing Mouse mAb**



www.bioss.com.cn

sales@bioss.com.cn

techsupport@bioss.com.cn

400-901-9800

### **— DATASHEET —**

<b>Host:</b> Mouse	<b>Isotype:</b> IgG1	<b>Applications:</b> ELISA (1:5000-10000)
<b>Clonality:</b> Monoclonal	<b>CloneNo.:</b> 7G10	<b>Reactivity:</b> SARS-CoV-2
<b>Target:</b> SARS-CoV-2 (2019-nCoV) Spike Neutralizing		
<b>Immunogen:</b> Recombinant SARS-CoV-2 Spike S1 Protein: 14-685/1213.		
<b>Purification:</b> affinity purified by Protein A		<b>Predicted MW.:</b> 140 kDa
<b>Concentration:</b> Lot Dependent		
<b>Storage:</b> Size : 100ug 0.01M PBS (pH7.4). Size : 200ug (PBS only) 0.01M PBS Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.		
<b>Background:</b> The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. Here, we analyze the D614G mutation in the context of a soluble S ectodomain construct.		

### **— SELECTED CITATIONS —**

- **[IF=2.5]** Feroza Begum. et al. A SARS-CoV-2 peptide antigen purified from bacteria and displayed in a high-density repetitive manner on a virus-like particle could generate anti-SARS-CoV-2 neutralizing antibodies unlike free peptide. BIOCHEM BIOPH RES CO. 2024 Dec;739:150579 ELISA ;Mouse. 39205338